Vigonvita Life Sciences (2630) Stock Overview
A commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
2630 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vigonvita Life Sciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$68.20 |
| 52 Week High | HK$97.00 |
| 52 Week Low | HK$51.00 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2630 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 3.2% | 5.2% | 1.8% |
| 1Y | n/a | 72.8% | 39.6% |
Return vs Industry: Insufficient data to determine how 2630 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2630 performed against the Hong Kong Market.
Price Volatility
| 2630 volatility | |
|---|---|
| 2630 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 2630's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2630's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Guanghui Tian | www.vigonvita.cn |
Vigonvita Life Sciences Co., Ltd., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its lead products include LV232, a first-in-class dual-target serotonin transporter/5-hydroxytryptamine 3 receptor modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RdRp inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection; TPN102, a voltage-gated sodium and calcium channels inhibitor, which is in Phase I clinical trial for the treatment epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, an antiviral nucleoside prodrug, which is in Phase I clinical trial for RNA viruses, including coronavirus, influenza virus, arenavirus, and RSV.
Vigonvita Life Sciences Co., Ltd. Fundamentals Summary
| 2630 fundamental statistics | |
|---|---|
| Market cap | HK$4.55b |
| Earnings (TTM) | -HK$231.49m |
| Revenue (TTM) | HK$12.96m |
Is 2630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2630 income statement (TTM) | |
|---|---|
| Revenue | CN¥11.83m |
| Cost of Revenue | CN¥8.35m |
| Gross Profit | CN¥3.49m |
| Other Expenses | CN¥214.89m |
| Earnings | -CN¥211.40m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.17 |
| Gross Margin | 29.47% |
| Net Profit Margin | -1,786.71% |
| Debt/Equity Ratio | 266.5% |
How did 2630 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 13:37 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vigonvita Life Sciences Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.